Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -178.92M | -179.44M | -155.20M | -148.97M | -206.81M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -24.94M | -1.07M | -8.12M | -20.03M | 41.10M |
| Change in Net Operating Assets | -5.09M | -5.12M | -5.93M | 7.13M | 11.54M |
| Cash from Operations | -208.94M | -185.63M | -169.25M | -161.87M | -154.18M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -463.74M | -86.83M | -143.48M | -66.61M | -48.87M |
| Cash from Investing | -463.74M | -86.83M | -143.48M | -66.61M | -48.87M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 781.62M | 326.53M | 314.32M | 227.37M | 239.96M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | 0.00 | 0.00 |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -220.00K |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -28.59M | -5.37M | -5.30M | -5.56M | -499.00K |
| Cash from Financing | 753.03M | 321.16M | 309.03M | 221.81M | 239.24M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -15.00K | 1.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 80.35M | 48.69M | -3.70M | -6.68M | 36.19M |